Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Xu, He N ^a,b   Nioka, Shoko ^b   Li, Lin Z ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Flavoprotein; Fp FAD; Heterogeneity; Imaging; Metabolism; Mitochondrial redox state; NADH; Precancer; PTEN null pancreas; Redox scanner

Indexed keywords

BIOLOGICAL MARKER; FLAVOPROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MITOCHONDRIAL REDOX STATE; MOUSE; NONHUMAN; NORMAL DISTRIBUTION; OXIDATION REDUCTION STATE; PANCREAS; PANCREAS CANCER; PRECANCER; PRIORITY JOURNAL; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 84876522654     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-6     Document Type: Article

References (75)

1. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta 2011, 1815(1):44-64. 3014374, 20888394.
2. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 2011, 40(5):644-652. 10.1097/MPA.0b013e31821ff741, 21673535.
3. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7(3):163-172. 10.1038/nrclinonc.2009.236, 20101258.
4. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006, 5(4):787-796. 10.1158/1535-7163.MCT-06-0005, 16648548.
5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011, 378(9791):607-620. 10.1016/S0140-6736(10)62307-0, 21620466.
6. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012, 3(2):105-119. 3397644, 22811878.
7. Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012, 18(17):2439-2451. 10.2174/13816128112092439, 3408036, 22372502.
8. Pezzilli R, Fabbri D, Imbrogno A. Pancreatic ductal adenocarcinoma screening: New perspectives. World J Gastroenterol 2012, 18(36):4973-4977. 10.3748/wjg.v18.i36.4973, 3460322, 23049204.
9. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11(2):85.
10. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11(5):325. 10.1038/nrc3038, 21508971.
11. Locasale J, Grassian A, Beroukhim R, Meyerson M, Wagner G, Asara J, Brugge J, Vander Heiden M, Cantley L. Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. BMC Proceedings 2012, 6(Suppl 3):O15.
12. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011, 14(4):443. 10.1016/j.cmet.2011.07.014, 3196640, 21982705.
13. Locasale JW, Cantley LC. Altered metabolism in cancer. BMC Biol 2010, 8:88. 10.1186/1741-7007-8-88, 2892450, 20598111.
14. Locasale JW, Cantley LC, Vander Heiden MG. Cancer's insatiable appetite. Nat Biotechnol 2009, 27(10):916-917. 10.1038/nbt1009-916, 19816448.
15. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033. 10.1126/science.1160809, 2849637, 19460998.
16. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329(5998):1492-1499. 10.1126/science.1188015, 3030121, 20847263.
17. Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011, 2(5):229-236. 3100499, 21611100.
18. Li LZ. Imaging mitochondrial redox potential and its possible link to tumor metastatic potential. J Bioenerg Biomembr 2012, 44:645-653. 10.1007/s10863-012-9469-5, 22895837.
19. Mullen AR, Deberardinis RJ. Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol Metab 2012, 23(11):552-559. 10.1016/j.tem.2012.06.009, 22858391.
20. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483(7390):474-478. 10.1038/nature10860, 3478770, 22343901.
21. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 2011, 17(11):641-649. 10.1016/j.molmed.2011.06.001, 3205302, 21764377.
22. Cardaci S, Ciriolo MR. TCA Cycle Defects and Cancer: When metabolism tunes redox state. Int J Cell Biol 2012, 2012:161837. 3408673, 22888353.
23. Chance B. Optical Method. Annu Rev Biophys Biophys Chem 1991, 20:1-28. 10.1146/annurev.bb.20.060191.000245, 1867711.
24. Chance B, Schoener B, Oshino R, Itshak F, Nakase Y. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J Biol Chem 1979, 254(11):4764-4771.
25. Gu Y, Qian Z, Chen J, Blessington D, Ramanujam N, Chance B. High-resolution three-dimensional scanning optical image system for intrinsic and extrinsic contrast agents in tissue. Rev Sci Instrum 2002, 73(1):172-178.
26. Li LZ, Xu HN, Ranji M, Nioka S, Chance B. Mitochondrial redox imaging for cancer diagnostic and therapeutic studies. J Innov Opt Health Sci 2009, 2:325-341.
27. Quistorff B, Haselgrove JC, Chance B. High spatial resolution readout of 3-D metabolic organ structure: an automated, low-temperature redox ratio-scanning instrument. Anal Biochem 1985, 148(2):389-400. 10.1016/0003-2697(85)90244-1, 4061818.
28. Chance B. Spectrophotometric and kinetic studies of flavoproteins in tissues, cell suspensions, mitochondria and their fragments. Flavins and Flavoproteins 1966, 498-510. Amsterdam: Elsevier, Slater EC.
29. Chance B, Baltscheffsky H. Respiratory Enzymes in Oxidative Phosphorylation. J Biol Chem 1958, 233(2):736-739.
30. Chance B, Williams GR. Method for the localization of sites for oxidative phosphorylation. Nature 1955, 176(4475):250-254. 10.1038/176250a0, 13244669.
31. Hassinen I, Chance B. Oxidation-reduction properties of the mitochondrial flavoprotein chain. Biochem Biophys Res Commun 1968, 31(6):895-900. 10.1016/0006-291X(68)90536-6, 4299232.
32. Li LZ, Zhou R, Xu HN, Moon L, Zhong T, Kim EJ, Qiao H, Reddy R, Leeper D, Chance B, Glickson JD. Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential. Proc Natl Acad Sci U S A 2009, 106(16):6608-6613. 10.1073/pnas.0901807106, 2672511, 19366661.
33. Xu HN, Nioka S, Glickson JD, Chance B, Li LZ. Quantitative mitochondrial redox imaging of breast cancer metastatic potential. J Biomed Opt 2010, 15(3):036010. 10.1117/1.3431714, 3188620, 20615012.
34. Li LZ, Zhou R, Zhong T, Moon L, Kim EJ, Qiao H, Pickup S, Hendrix MJ, Leeper D, Chance B, Glickson JD. Predicting melanoma metastatic potential by optical and magnetic resonance imaging. Adv Exp Med Biol 2007, 599:67-78. 10.1007/978-0-387-71764-7_10, 17727249.
35. Xu HN, Zhou R, Nioka S, Chance B, Glickson JD, Li LZ. Histological basis of MR/optical imaging of human melanoma mouse xenografts spanning a range of metastatic potentials. Adv Exp Med Biol 2009, 645:247-253. 10.1007/978-0-387-85998-9_37, 19227478.
36. Drezek R, Brookner C, Pavlova I, Boiko I, Malpica A, Lotan R, Follen M, Richards-Kortum R. Autofluorescence microscopy of fresh cervical-tissue sections reveals alterations in tissue biochemistry with dysplasia. Photochem Photobiol 2001, 73(6):636-641. 10.1562/0031-8655(2001)0730636AMOFCT2.0.CO2, 11421069.
37. Skala MC, Riching KM, Gendron-Fitzpatrick A, Eickhoff J, Eliceiri KW, White JG, Ramanujam N. In vivo multiphoton microscopy of NADH and FAD redox states, fluorescence lifetimes, and cellular morphology in precancerous epithelia. Proc Natl Acad Sci U S A 2007, 104(49):19494-19499. 10.1073/pnas.0708425104, 2148317, 18042710.
38. Ramanujam N, Richards-Kortum R, Thomsen S, Mahadevan-Jansen A, Follen M, Chance B. Low Temperature Fluorescence Imaging of Freeze-trapped Human Cervical Tissues. Opt Express 2001, 8(6):335-343. 10.1364/OE.8.000335, 19417824.
39. Stanger BZ, Stiles B, Lauwers GY, Bardeesy N, Mendoza M, Wang Y, Greenwood A, Cheng KH, McLaughlin M, Brown D, DePinho RA, Wu H, Melton DA, Dor Y. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8(3):185-195. 10.1016/j.ccr.2005.07.015, 16169464.
40. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008, 10(8):782-796. 2481568, 18670639.
41. Younes M, Lauwers GY, Ertan A, Ergun G, Verm R, Bridges M, Woods K, Meriano F, Schmulen C, Johnson C, Barroso A, Schwartz J, McKechnie J, Lechago J. The significance of "indefinite for dysplasi" grading in Barrett metaplasia. Arch Pathol Lab Med 2011, 135(4):430-432.
42. Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, van Vuuren AJ, Bode WA, van der Valk H, Ouwendijk RJ, Giard R, Lesterhuis W, Heinhuis R, Klinkenberg EC, Meijer GA, ter Borg F, Arends JW, Kolkman JJ, van Baarlen J, de Vries RA, Mulder AH, van Tilburg AJ, Offerhaus GJ, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol 2011, 106(7):1231-1238. 10.1038/ajg.2011.153, 21577245.
43. Xu HN, Nioka S, Chance B, Li LZ. Heterogeneity of mitochondrial redox state in premalignant pancreas in a PTEN null transgenic mouse model. Adv Exp Med Biol 2011, 701:207-213. 10.1007/978-1-4419-7756-4_28, 21445789.
44. Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, Beg AA, Tergaonkar V, Chandel NS, Franzoso G. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol 2011, 13(10):1272-1279. 10.1038/ncb2324, 3462316, 21968997.
45. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996, 93(8):3636-3641. 10.1073/pnas.93.8.3636, 39663, 8622988.
46. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998, 21(2):81-86. 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R, 9496907.
47. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003, 89(11):2110-2115. 10.1038/sj.bjc.6601396, 2376856, 14647146.
48. Yoshimoto M, Ludkovski O, DeGrace D, Williams JL, Evans A, Sircar K, Bismar TA, Nuin P, Squire JA. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes, Chromosomes and Cancer 2012, 51(2):149.
49. Acharya A, Das I, Chandhok D, Saha T. Redox Regulation in Cancer: a double-edged sword with therapeutic potential. Oxidative Medicine and Cellular Longevity 2010, 3(1):23-34. 10.4161/oxim.3.1.10095, 2835886, 20716925.
50. Grek CL, Tew KD. Redox metabolism and malignancy. Curr Opin Pharmacol 2010, 10(4):362-368. 10.1016/j.coph.2010.05.003, 2930777, 20627682.
51. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008, 320(5876):661-664. 10.1126/science.1156906, 18388260.
52. Pani G, Giannoni E, Galeotti T, Chiarugi P. Redox-based escape mechanism from death: the cancer lesson. Antioxid Redox Signal 2009, 11(11):2791-2806. 10.1089/ars.2009.2739, 19686053.
53. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, Huang P. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res 2009, 69(6):2375-2383. 10.1158/0008-5472.CAN-08-3359, 2760349, 19276362.
54. Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW, Goodman RH. Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci U S A 2006, 103(24):9029-9033. 10.1073/pnas.0603269103, 1482560, 16740659.
55. Ishikawa K, Koshikawa N, Takenaga K, Nakada K, Hayashi J. Reversible regulation of metastasis by ROS-generating mtDNA mutations. Mitochondrion 2008, 8(4):339-344. 10.1016/j.mito.2008.07.006, 18727959.
56. Ohsawa S, Sato Y, Enomoto M, Nakamura M, Betsumiya A, Igaki T. Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. Nature 2012, 490(7421):547-551. 10.1038/nature11452, 23023132.
57. Imanishi H, Hattori K, Wada R, Ishikawa K, Fukuda S, Takenaga K, Nakada K, Hayashi J. Mitochondrial DNA mutations regulate metastasis of human breast cancer cells. PLoS One 2011, 6(8):e23401. 10.1371/journal.pone.0023401, 3154938, 21853128.
58. Hyodo F, Matsumoto K, Matsumoto A, Mitchell JB, Krishna MC. Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res 2006, 66(20):9921-9928. 10.1158/0008-5472.CAN-06-0879, 17047054.
59. Keshari KR, Kurhanewicz J, Bok R, Larson PE, Vigneron DB, Wilson DM. Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc Natl Acad Sci U S A 2011, 108(46):18606-18611. 10.1073/pnas.1106920108, 3219134, 22042839.
60. Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010, 29(2):351-378. 10.1007/s10555-010-9225-4, 20386957.
61. Veech RL. The determination of the redox states and phosphorylation potential in living tissues and their relationship to metabolic control of disease phenotypes. Biochem Mol Biol Educ 2006, 34(3):168-179. 10.1002/bmb.2006.49403403168, 21638666.
62. Fidler IJ. Review: biologic heterogeneity of cancer metastases. Breast Cancer Res Treat 1987, 9(1):17-26. 10.1007/BF01806690, 3297212.
63. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982, 217(4564):998-1003. 10.1126/science.7112116, 7112116.
64. Heppner GH. Tumor Heterogeneity. Cancer Res 1984, 44(6):2259-2265.
65. Heppner GH, Miller FR. The cellular basis of tumor progression. Int Rev Cytol 1998, 177:1-56.
66. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892. 10.1056/NEJMoa1113205, 22397650.
67. Diaz-Cano SJ. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 2012, 13(2):1951-2011. 10.3390/ijms13021951, 3292002, 22408433.
68. Keller PJ, Lin A, Arendt LM, Klebba I, Jones AD, Rudnick JA, Dimeo TA, Gilmore H, Jefferson DM, Graham RA, Naber SP, Schnitt S, Kuperwasser C. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 2010, 12(5):R87. 10.1186/bcr2755, 3096980, 20964822.
69. O'Connor JP, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F, Whitcher BJ, Roberts C, Buonaccorsi GA, Thompson G, Clamp AR, Jayson GC, Parker GJ. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 2011, 105(1):139-145. 10.1038/bjc.2011.191, 3137409, 21673686.
70. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, Imamura M, Konishi J. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality". Ann Nucl Med 2003, 17(4):261-279. 10.1007/BF02988521, 12932109.
71. Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, Sahani DV, Fischman AJ, Mueller PR. Pearls and Pitfalls in Interpretation of Abdominal and Pelvic PET-CT1. Radiographics 2006, 26(5):1335-1353. 10.1148/rg.265055208, 16973768.
72. Guynn RW, Pieklik JR. Dependence on dose of the acute effects of ethanol on liver metabolism in vivo. J Clin Invest 1975, 56(6):1411-1419. 10.1172/JCI108222, 333119, 422.
73. Weber G, Stubbs M, Morris HP. Metabolism of hepatomas of different growth rates in situ and during ischemia. Cancer Res 1971, 31(12):2177-2183.
74. Xu HN, Wu B, Nioka S, Chance B, Li LZ. Calibration of redox scanning for tissue samples. Biomedical Optics: Jan. 24 2009 2009, 71742F. San Jose, CA: SPIE.
75. Xu HN, Wu B, Nioka S, Chance B, Li LZ. Quantitative redox scanning of tissue samples using a calibration procedure. J Innov Opt Health Sci 2009, 2:375-385.